Organon's Third-Quarter Adjusted Earnings Slip To $0.94 A Share, And There Is No Earnings Call

Adjusted EBITDA fell to $502 million from $518 million as the pending Sun Pharmaceutical merger replaced the usual release and call.

Share
Organon's Third-Quarter Adjusted Earnings Slip To $0.94 A Share, And There Is No Earnings Call

Organon, the prescription-medicine maker behind the Nexplanon contraceptive implant, posted adjusted diluted earnings of $0.94 a share for the third quarter, down from $1.01 a year earlier. The company put the numbers out in an 8-K filed Friday rather than an earnings release or call, which it suspended because of its pending merger with Sun Pharmaceutical Industries Limited.

Adjusted measures slip, reported ones hold

Adjusted EBITDA, which strips out one-time items, stock pay and similar costs, came to $502 million in the quarter, against $518 million a year earlier. The adjusted EBITDA margin was 31.9%, versus 32.3%.

Adjusted net income was $256 million, against $263 million. Adjusted gross margin was 59.6%, down from 60.3%.

Standard-accounting results moved the other way or held flat. Net income was $164 million versus $160 million, and gross margin rose to 55.2% from 53.5%. Standard diluted earnings per share were $0.60, against $0.61.

The gap between the two views narrowed: adjustments added $0.34 a share this quarter, against $0.40 a year earlier.

Nine months show a sharper decline

Over the first nine months, adjusted net income fell to $674 million from $789 million. Adjusted EBITDA dropped to $1.378 billion from $1.524 billion, and its margin to 30.0% from 32.4%.

Adjusted diluted earnings per share for the nine months were $2.51, against $3.03. Standard earnings per share rose to $1.56 from $1.50.

The nine-month adjusted figures exclude an $81 million gain from the Jada divestiture, which is removed from the total.

Deal costs and manufacturing exits

Other costs added back in the quarter included $19 million tied to the pending Sun Pharmaceutical transaction. For the nine months, that figure was $30 million, plus $17 million from an unfavorable resolution of a working-capital matter on the Dermavant acquisition.

Manufacturing network costs, from exiting supply agreements with Merck, were $23 million in the quarter, against $46 million a year earlier.

Organon sells more than 70 products in women's health and general medicines. In 2025, its revenue was $6.2 billion, about 74% of it from outside the United States, according to its annual report.

Organon filed its full quarterly report with the SEC on Friday, the same day as the supplemental adjusted figures.

Sources

More on Organon

All Organon (OGN) coverage →